ERBB2 and neoplasm: In the fully adjusted models 5A–5C, the risk of death was higher among patients who had had an HER2+ or unclassified immunohistochemical profile (vs ER/PR+), poorly differentiated tumours, comorbidities, a tumour that was not screen detected and an advanced or unknown stage at diagnosis.